Search
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … Ataluren is a novel, orally administered drug that targets nonsense mutations.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acidLC16M8
go.drugbank.com/drugs/DB05019InvestigationalLC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. … It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection.
Besifovir dipivoxil
go.drugbank.com/drugs/DB05020InvestigationalBesifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. … Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Categories: Heterocyclic Compounds, 2-RingLunacalcipol
go.drugbank.com/drugs/DB05024InvestigationalCTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. … This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways.
Anatibant
go.drugbank.com/drugs/DB05038ExperimentalAnatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
Categories: Heterocyclic Compounds, 2-RingPSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
DDP733
go.drugbank.com/drugs/DB05049InvestigationalIt is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).
Categories: Heterocyclic Compounds, 1-RingEGS21
go.drugbank.com/drugs/DB05056ExperimentalEGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. … GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate
Erdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine is a drug that causes a breakdown of mucus, also known as a _mucolytic_ agent. … Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.
Categories: Heterocyclic Compounds, 1-RingProducts: DOSTEIN® CAPSULAS, DOSTEIN® SUSPENSIONILY101
go.drugbank.com/drugs/DB05059InvestigationalILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. … ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs.